Use of TGF-beta antagonists in the treatment of infants at risk of developing bronchopulmonary dysplasia

摘要

The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-² antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-² antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.